• +86-0635-6175299
  • li_ye@inyelchem.com
    •
  • Company Details

     Shandong Haohong Biotechnology Co., Ltd.

     [Shandong,China]

    Business Type:Manufacturer

    Main Markets: Americas , Asia , East Europe , Europe , Middle East , North Europe , West Europe , Worldwide

    Exporter:71% - 80%

    Certs:Test Report, ISO9001

    Description:Crpc Intermediate Cas 654-70-6,Crpc Drug Intermediate Cas 403-24-7,Pharma Intermedaite Cas 915087-25-1,Apalutamide Intermediates,prostate cancer

    Language

 Shandong Haohong Biotechnology Co., Ltd.

All
  • All
  • Title
All
  • All
  • Title
HomeProductsCRPC Drug
PRODUCT CATEGORIES

CRPC Drug

More

Apalutamide Intermediates

More

Enzalutamide Intermediates

More

Bicalutamide Intermediate

China leading manufacturers and suppliers of Crpc Intermediate No 654-70-6,Crpc Drug Intermediate Cas 403-24-7, Pharma Intermedaite Cas 915087-25-1,and we are specialized in Pharma Intermedaite Cas 654-70-6,Apalutamide Intermediates, etc,which is used for prostate cancer.If you want to buy Pharma Intermedaite Cas 654-70-6,Apalutamide Intermediates,please contact us.

Apalutamide (INN) (developmental code name ARN-509, also JNJ-56021927) is a non-steroidal antiandrogen that is under development for the treatment of prostate cancer. It is similar to enzalutamide both structurally and pharmacologically, acting as a selective competitive antagonist of the androgen receptor (AR), but shows some advantages, including greater potency and reduced central nervous system permeation. Apalutamide binds weakly to the GABAA receptor similarly to enzalutamide, but due to its relatively lower central concentrations, may have a lower risk of seizures in comparison.

The drug has been found to be effective and well-tolerated in clinical trials thus far, with the most common side effects reported including fatigue, nausea, abdominal pain, and diarrhea.
Apalutamide is currently in phase III clinical trials for castration-resistant prostate cancer.

Recently, the acquired F876L mutation of the AR identified in advanced prostate cancer cells was found to confer resistance to both enzalutamide and apalutamide. A newer antiandrogen, darolutamide (ODM-201), is not affected by this mutation, nor has it been found to be affected by any other tested/well-known AR mutations.; Apalutamide may be effective in a subset of prostate cancer patients with acquired resistance to abiraterone acetate.

Our CRPC Drug is as following,we have all the below API and intermedites offering all year.

Apalutamide API and intermedites:

Apalutamide Cas No 403-24-7;Apalutamide Cas 951753-87-0;Apalutamide Cas 915087-25-1;

Apalutamide Cas 749927-69-3;Apalutamide Cas 573762-62-6;Apalutamide Cas 956104-40-8;

 Bicalutamide API and intermedites:

 Bicalutamide Cas No 654-70-6;Bicalutamide Cas No 90357-53-2;

 Enzalutamide  API and intermedites:

Enzalutamide Cas No 403-24-7;Enzalutamide Cas No 112704-79-7;Enzalutamide Cas No 749927-69-3;Enzalutamide Cas No 915087-25-1;

Enzalutamide Cas No 143782-23-4; Enzalutamide Cas No 1289942-66-0;Enzalutamide Cas No 1332524-01-2;

Enzalutamide Cas No 915087-32-0;Enzalutamide Cas No 915087-33-1;

Home > Products > CRPC Drug
 Shandong Haohong Biotechnology Co., Ltd.

Related Products List

Contact Us

Kelly
Name: Ms. Kelly
Email: li_ye@inyelchem.com
Tel: +86-0635-6175299
Address No.5,North Guandao street,Gaotang County, Liaocheng, Shandong

Mobile Site

Copyright © 2024  Shandong Haohong Biotechnology Co., Ltd. All rights reserved .  Privacy Policy

Home

Product

Whatsapp

About Us

Inquiry
Please Leave Us A Message

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

We will contact you immediately

Fill in more information so that we can get in touch with you faster

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

Upload Attachment
Send